BRIEF—Immunocore in $140 million private placement financing

Anglo-American company Immunocore, a biotech developing a novel class of T cell receptor bispecific immunotherapies designed to treat a broad range of diseases, including cancer, autoimmune and infectious diseases, has announced a $140 million private placement financing.

Immunocore expects to use the proceeds from the private investment in public equity to fund its oncology and infectious disease clinical pipeline including the continued clinical development of tebentafusp in advanced cutaneous melanoma and ImmTAC clinical candidates targeting MAGE-A4 and PRAME.

The funds are expected to pay for Immunocore’s current operating plan through 2025.